Kineta Invited to Participate in the Cowen 42nd Annual Health Care Virtual Conference Seattle, WA — (February 24, 2021) Kineta,

Seattle, WA — (January 24, 2022) Kineta, Inc., a clinical stage biotechnology company focused on the development of novel immunotherapies

Kineta to Present at the H.C. Wainwright Bioconnect Virtual Conference Seattle, WA — (January 11 , 2022) Kineta, Inc., a

Kineta Presented New Preclinical Data on its Anti-CD27 Agonist Antibody Program at the ESMO Immuno-oncology Congress 2021 Seattle, WA —

Kineta Presents Phase 1/2 Clinical Trial Design of KVA12.1 at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting

Kineta Presented Compelling Preclinical Data on its New CD27 Antibody Program at the 2021 SITC Annual Meeting Seattle, WA —

Kineta Presents Preclinical Data on its New CD27 Program at the AACR Conference on Tumor Immunology and Immunotherapy Kineta expands

Kineta Announces Poster Presentation at the 2021 American Association for Cancer Research Conference on Tumor Immunology and Immunotherapy Seattle, WA —

Kineta Announces Participation at H.C. Wainwright 23rd Annual Global Investment Conference Seattle, WA — (August 30, 2021) Kineta, Inc., a